AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03982134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Panobinostat is a Histone deacetylase inhibitor (HDACi).
Study NCT03372759 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: airtamponade
Description: airtamponade is applicated in the study group air
Study NCT03372759 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: saline
Description: saline is left in the study Group saline
Study NCT01954927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Gabapentin is supplied as an oral suspension. Patients randomized to the gabapentin arm will receive a single dose of gabapentin as soon after enrollment as feasible. The gabapentin dose will be given orally and will be approximately 15 mg/kg with a maximum dose of 900 mg.
Study NCT01954927 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be prepared by the SJCRH pharmacy and will be similar in appearance, quantity and taste to the gabapentin drug. Patients randomized to the placebo arm will receive a single dose of placebo as soon after enrollment as feasible. The placebo dose will be given orally and will be approximately 15 mg/kg with a maximum dose of 900mg.
Study NCT00689260 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: easypod
Description: Subjects is aware that the device records injection information that can be viewed by user
Study NCT02104414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel
Description: 266 mg/20mL Exparel (to be diluted with 10 mL sterile saline to make 30 mL)
Study NCT02104414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl with Epinephrine
Description: 75mg/30mL 0.25% Bupivacaine HCl with epinephrine
Study NCT02104414 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 30mL Normal Saline
Study NCT04782167 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRACE
Description: Balance training,Static balance:~1. Romberg with eye open \& eye close \[30 sec repeat 3 times\]~2. Tandem standing with eye open then with eye close. Right foot front first, then left foot front \[10 Sec repeat 3 times\]~3. Single leg stance 5 repetition with sec.~Static/Dynamic/Anti-cipatory Postural Control:~1. Sit to stand: 5 repetition~2. Functional reach test: forward, sideways \& cross reach, practice 1 min for each~3. TUG test: with distance of 10 feet \& time 10 sec. practice 2 min Cognitive exercises~1) Count reverse from 50 Repeat with eyes open and close Reps of 30s for each 2) Push wall and reverse count from 20 3) Remember 5 words, Name 5 animals, Repeat 5 words
Study NCT04782167 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Propirioceptive training
Description: 1st Phase - Steady phase (1st set: Eyes Open, 2nd set: Eyes Close) Preserve standup position Equally heels up and down Preserve standup on one leg by turns
Study NCT00430755 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Computer-assisted history
Description: Methods The intervention was use of an expert system to acquire medical histories by direct interview of patients.~Description of the software program - The program tested in this study consisted of a data acquisition \[history-taking\] component and a data analysis component. The data acquisition component was constructed on the basis of established principles of pathophysiology. Medical knowledge was formalized as software algorithms that were machine-readable by representing the knowledge as branched chain decision trees.
Study NCT00430755 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: physician taken history
Description: Convential history taking by physicians
Study NCT00430755 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Computer-assisted history taking
Study NCT02733029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonazoid
Description: Sonazoid (GE Healthcare) is a contrast agent that is a lipid-stabilized suspension of perfluorobutane microbubbles
Study NCT02733029 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: contrast enhanced ultrasonography
Description: Injection of intravenous ultrasound contrast
Study NCT03902080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vibegron
Description: oral administration
Study NCT03902080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration
Study NCT00450944 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins
Study NCT03346174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AAD
Description: In this controlled trial with intra-subject design infants will be studied using multichannel intraluminal impedance pH (pH-MII) monitoring , during which they receive one 20 min session of AAD . The number of reflux episodes (RE) is the outcome measure. The results obtained during and 20 min after the intervention will be compared to a period of 20 min before treatment ( control ).
Study NCT03346174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BAAD
Description: In this controlled trial with intra-subject design infants will be studied using multichannel intraluminal impedance pH (pH-MII) monitoring , during which they receive one 20 min session of BAAD . The number of reflux episodes (RE) is the outcome measure. The results obtained during and 20 min after the intervention will be compared to a period of 20 min before treatment ( control ).
Study NCT00463476 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine (LJEV)
Description: Manufactured by Chengdu Institute of Biological Products (CDIBP), Chengdu, China; batch 200611A078-1. Administered subcutaneously in the right upper arm using 23 gauge needles.
Study NCT01505894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet
Study NCT00689260 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: easypod
Description: Subjects is not aware that the device records injection information that can be viewed by user
Study NCT01486082 — intervention group
Intervention type: OTHER
Intervention: OCA 10
Description: A group will be treated with omeprazole (20 mg / 12 h), amoxicillin (1 g/ 12 h)and clarithromycin (500 mg/12 h) for 10 days (as following current guides) without having a previous antibiogram, and the other group will be treated after antibiotic susceptibility.
Study NCT01221285 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: German cockroach (Blattella germanica) allergenic extract
Description: Participants received weekly escalating doses of glycerinated German cockroach allergenic extract administered via the subcutaneous route up to a Maximum Study Dose of 0.6 mL of extract at a concentration of 1:20 wt/vol.
Study NCT00842907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral isotretinoin
Description: one 20.0 mg capsule, once a day, every other day, during 24 weeks
Study NCT00842907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tretinoin
Description: 0.05% tretinoin cream applied on face and forearms, once a day, in the night, during 24 weeks
Study NCT06531889 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: classical physiotherapy program
Description: Classical physiotherapy program=Classical physiotherapy program included transcutaneous electrical nerve stimulation, infrared radiation for 15 min, continuous ultrasound for 5 min and home exercise program. For active assistive shoulder range of motion (ROM), home exercises included the Codman exercise, flexion exercise at the ladder, and the Wand exercise, as well as some strengthening and stretching exercises performed at the pain limit with 10 repetitions twice a day (six weeks)
Study NCT06531889 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: classical physiotherapy program
Description: Classical physiotherapy program=Classical physiotherapy program included transcutaneous electrical nerve stimulation, infrared radiation for 15 min, continuous ultrasound for 5 min and home exercise program. For active assistive shoulder range of motion (ROM), home exercises included the Codman exercise, flexion exercise at the ladder, and the Wand exercise, as well as some strengthening and stretching exercises performed at the pain limit with 10 repetitions twice a day (six weeks)
Study NCT06531889 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Stabilization Exercises
Description: The interventions of the core exercise were applied when the patient lay on his/her back with his/her knees at flexion. The number of repeats for each exercise was five, and these exercises were done 3 times a week for 6 weeks with the same physiotherapist. The further steps in the exercises were extended according to the activation duration of the core muscles, and this extension was elongated 5 s
Study NCT02730195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Given PO
Study NCT04419311 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vanguard® Knee System
Description: Posterior cruciate ligament retention versus sacrificing is one of the main debates in total knee arthroplasty (TKA) and retention or sacrificing depends on the individual preference of the surgeon during the surgery. Whenever the surgeon decides to sacrifice the posterior cruciate ligament (PCL), another controversial question arises regarding the tibial insert type. While the posterior cruciate ligament-stabilized (PS) insert is widely used as the tibial insert in PCL-sacrificing TKA, it has some disadvantages such as increased polyethylene wear, additional bone resection, breakage of the post and patellar clunk syndrome. The ultra-congruent (UC) insert was designed to prevent bone loss in particular, and the other mentioned disadvantages of the conventional PS insert. However, patients with postoperative hyperextension have been seen to be associated with inferior clinical outcomes and knees become gradually more extended until two years after TKA using the UC insert.
Study NCT02730195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyrosine Kinase Inhibitor (TKI)
Description: Given TKI therapy
Study NCT03354143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 130 mmHg.
Study NCT03354143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive Treatment
Description: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 120 mmHg.
Study NCT02847676 — intervention group
Intervention type: PROCEDURE
Intervention: Tissue sample donation
Description: Patients undergo planned gynaecological surgery. Tissue samples, which are routinely taken, are donated.
Study NCT01795768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD 4547
Study NCT02735824 — intervention group
Intervention type: PROCEDURE
Intervention: blood sampling and skin biopsy
Description: Nucleated blood cells and/or fibroblasts from skin biopsy will be used for genetic testing and functional assays. Blood serum will be used for antibody and cytokine measurement.
Study NCT02735824 — intervention group
Intervention type: PROCEDURE
Intervention: blood sampling or mouth swap
Description: specimen will be used for genetic testing, results compared to patients
Study NCT02735824 — intervention group
Intervention type: PROCEDURE
Intervention: blood sampling
Description: Nucleated blood cells and/or fibroblasts from skin biopsy will be used for genetic testing and functional assays. Blood serum will be used for antibody and cytokine measurement.
Study NCT00995033 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NicVAX vaccine
Description: NicVAX vaccine given 6 times over 6 months
Study NCT00995033 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate buffered saline and ALhydrogel of identical appearance to NicVAX; IM in 6 doses over 6 months
Study NCT00995033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Days 0-2: 0.5 mg once daily, Days 3-6: 0.5 mg twice daily (morning and evening), Day 7- 84: 1.0 mg twice daily (morning and evening)
Study NCT00995033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Varenicline
Description: Days 0-2: 0.5 mg once daily, Days 3-6: 0.5 mg twice daily (morning and evening), Day 7- 84: 1.0 mg twice daily (morning and evening)
Study NCT03246997 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Autumn Group
Description: The intervention is participating in a fruit and vegetable farm share for 6 months.
Study NCT03246997 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Spring Group
Description: The intervention is participating in a fruit and vegetable farm share for 6 months.
Study NCT03636841 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: medical device with CE marking (Ultravision ©)
Description: Ultravision © is a medical device that is used during laparoscopy to reduce the discomfort caused by surgical smoke produced by the electrical section of tissue. It works by using the principle of electrostatic precipitation, that is to say it causes the precipitation of suspended smoke droplets on the organs and walls of the abdomen.
Study NCT03636841 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: medical device with CE marking (Ultravision ©)
Description: Ultravision © is a medical device that is used during laparoscopy to reduce the discomfort caused by surgical smoke produced by the electrical section of tissue. It works by using the principle of electrostatic precipitation, that is to say it causes the precipitation of suspended smoke droplets on the organs and walls of the abdomen.
Study NCT02329340 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Am Academy of Pediatrics print materials
Description: Print materials of injury prevention content.
Study NCT02329340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family safety 1-2-3
Description: Theoretically based school-aged childhood injury prevention videos for families
Study NCT01239992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin/ Laropiprant
Description: 1000/ 20 mg first 4 weeks, 2000/40 mg next 8 weeks; daily
Study NCT02810444 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IgG Next Generation (BT595)
Study NCT04427826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine hydrochloride
Description: A single open-label injection of morphine (T0) at the dose closest to that defined by the model (estimation by Bayesian method) from among the following 4 doses: 0.02; 0.04; 0.07 and 0.1mg/kg will be adminestred to the patients.
Study NCT05154305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multidisciplinary intervention
Description: * individually adjusted physical program consisting of strength and endurance training > 3 times a week, 2 times guided by a physical therapist at the University Hospital or at a private practice, and ones a week by themselves at home recorded by an activity tracker. Follow-up is foreseen on monthly basis.~* multidisciplinary coaching (discipline depending on personal needs of patient) on a monthly basis. These coaching sessions could be in small groups or individual.
Study NCT02785770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04447943
Description: Single oral dose of PF-04447943 administered as an extemporaneously prepared solution
Study NCT02785770 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral dose of matching placebo for PF-04447943 administered as an extemporaneously prepared solution
Study NCT02785770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Single oral dose of moxifloxacin administered as tablet
Study NCT01696162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Algorithm based Exercise Videos
Description: The algorithm will adjust the exercises in each session based upon the participant's feedback.
Study NCT01696162 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PDF Exercise Sheets
Description: A sheet of six exercises with descriptions on how to perform them properly
Study NCT01696162 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Limited Exercise Videos
Description: Video of 6 exercises that provide instruction on how to perform the exercises
Study NCT01215929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextroamphetamine
Description: Thirty treatment-seeking methamphetamine dependent volunteers will be admitted to a residential facility and be inducted onto d-amphetamine during week 1 of the study. 15 Participants then will be randomized by severity of methamphetamine dependence, sex, amphetamine withdrawal questionnaire score and history of Attention Deficit Hyperactivity Disorder to receive oral d-amphetamine at a dose of 30 mg twice daily for 2 weeks.
Study NCT01215929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Thirty treatment-seeking methamphetamine dependent volunteers will be admitted to a residential facility in this 4-week, double-blind, placebo-controlled, clinical trial and be inducted onto d-amphetamine during week 1 of the study. 15 Participants then will be randomized by severity of methamphetamine dependence, sex, amphetamine withdrawal questionnaire score and history of Attention Deficit Hyperactivity Disorder to receive oral placebo tablets twice daily for 2 week.
Study NCT01594801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InsuPad
Description: Use of the InsuPad for at least 3 times a day.
Study NCT00855270 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV saline will be used as placebo for control
Study NCT00855270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: A single dose 90-150mg of Intra Venous Hydrocortisone. 90mg will be administrated to participants weighing 45-59kg. 100mg will be administrated to participants weighing 60-69kg. 120mg will be administrated to participants weighing 70-89kg. 140mg will be administrated to participants weighing 90-99kg. 150mg will be administrated to participants weighing 100-120kg.
Study NCT03827044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab is a fully human monoclonal antibody (MoAb) of the immunoglobulin G (IgG) 1 subtype which specifically binds to the PD-L1 cell surface ligand and blocks its interaction with the PD-1 cell surface receptor.
Study NCT02879331 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 10 coils in upper lobes
Study NCT02879331 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 15 coils in upper and lower lobes
Study NCT02879331 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cycloergometry
Study NCT02879331 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cycloergometry
Study NCT02600871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Provodine
Study NCT02600871 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Incision and Drainage
Study NCT02600871 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incision and Drainage
Study NCT03537469 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CTU Mega 20 real device
Description: The CTU Mega 20 diamagnetic acceleration system discharges high-field magnetic impulses (with a duration of 5 ms and a period of 1000 ms), generating a magnetic field up to 2 Tesla, with a frequency of 7500 Hz in a volume of approximately 27 cm3.
Study NCT03537469 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CTU Mega 20 sham device
Description: A CTU Mega 20 sham device (with an identical appearance to that of the real device) to avoid treatment identification by the patient or experimenter was used. Of course, the application of this sham device did not provide any magnetic field.
Study NCT01627834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropinirole
Study NCT01627834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole
Study NCT04802629 — intervention group
Intervention type: DEVICE
Intervention: Near-infrared spectroscopy
Description: For NIRS measurements the t-NIRS 1 and NIRO 200 NX (Hamamatsu, Japan) will be used. A cerebral sensor will be placed and fixed with a CPAP (Continuous Positive Airway Pressure) cap on the left forehead and a peripheral sensor on the right forearm. Duration of measurement will be two hours.
Study NCT01976039 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: rhinopharyngeal retrograde clearance (RRC)
Description: The rhinopharyngeal retrograde clearance is a respiratory physical therapy technique that uses a forced inspiratory maneuver to clear the nasopharynx with the aid of saline instillation
Study NCT01976039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rhinopharyngeal retrograde clearance (RRC)
Description: The rhinopharyngeal retrograde clearance is a respiratory physical therapy technique that uses a forced inspiratory maneuver to clear the nasopharynx with the aid of saline instillation
Study NCT01688206 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab [TECENTRIQ]
Description: Participants will receive atezolizumab at a fixed dose of 840 mg, intravenously every 2 weeks.
Study NCT01688206 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vanucizumab
Description: Participants will receive escalating doses of vanucizumab (starting dose: 3 milligram \[mg\] per kilogram) and fixed dose of vanucizumab (MTD/RP2D: 30 mg/kg), intravenously every 2 weeks.